Skip to Main Content
American Flag
LABOR DAY SALE

50% off your first year of any Quiver subscription

...

Use Promo Code:

LABOR26
American Flag

Caribou Biosciences, Inc. Common Stock

CRBU Real Time Price USD
N/A
N/A
N/A
...
Overview
Financials
Forecast
Insiders
Institutions
Compensation
Government
Ownership
News
Income
Balance Sheet
Cash Flow
Revenue Breakdown

Recent trades of CRBU by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
CRBU Stock Insider Trading Activity Follow @QuiverQuant for major insider updates

---

Closing Price
Purchase
Sale
Name
Type
Shares
Price
Shares Held
Date
Reported
CRBU Stock Institutional Owners
Investor
Shares
Change in Shares
Market Value
Date
Reported
CRBU Derivatives Institutional Owners
Investor
Type
Shares
Change in Shares
Market Value
Date
Reported

Recently reported changes in CRBU holdings by institutional investors

Quarterly net insider trading by CRBU's directors and management

* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.

About

Backtest Start Date
CAGR (Total)
Return (30d)
Return (1Y)
  • 1M
  • 3M
  • 6M
  • YTD
  • 1Y
  • 2Y
  • 5Y
  • MAX

About

Backtest Start Date

Key Metrics

Return (1d)

Return (30d)

Return (1Y)

CAGR (Total)

Max Drawdown

Beta

Alpha

Sharpe Ratio

Win Rate

Average Win

Average Loss

Annual Volatility

Annual Std Dev

Information Ratio

Treynor Ratio

Total Trades

Show More
Metrics Definitions

Disclaimer: The performance results shown are based on historical backtesting and are hypothetical in nature. Backtested performance does not represent actual trading and does not account for all market factors that may affect execution, such as liquidity, slippage, and changing market conditions. Past performance is not necessarily indicative of future results. There is no guarantee that any trading strategy will be profitable or avoid losses.

  • Alpha

    Measures a portfolio's risk-adjusted performance against that of its benchmark

    Learn More about Alpha
  • Annual Standard Deviation

    Measures how much the portfolio's total return varies from its mean or average.

    Learn More about Annual Standard Deviation
  • Annual Volatility

    A statistical measure of the dispersion of returns for the portfolio.

    Learn More about Annual Volatility
  • Average Win

    The average return (%) for trades that resulted in a positive return.

  • Average Loss

    The average return (%) for trades that resulted in a negative return.

  • Beta

    A measure of the volatility of the portfolio compared to the market as a whole.

    Learn More about Beta
  • CAGR

    CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.

    Learn More about CAGR
  • Information Ratio

    A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.

    Learn More about Information Ratio
  • Max Drawdown

    the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.

    Learn More about Max Drawdown
  • Sharpe Ratio

    The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.

    Learn More about Sharpe Ratio
  • Total Trades

    The total number of trades made by this strategy.

  • Treynor Ratio

    Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.

    Learn More about Treynor Ratio
  • Win Rate

    The percentage of total trades that resulted in a positive return.

Subscribe to Quiver Premium for insider trading alerts

Be the first to see our newest insights and key updates across all datasets.

schema-2

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard

Former government officials who have lobbied for CRBU

Quiver Logo

No former government officials on record as having lobbied for CRBU

Revolving Door Dashboard

CRBU Estimated quarterly lobbying spending

Quiver Logo

No Corporate Lobbying data for this ticker

Corporate Lobbying Dashboard

CRBU Revenue by Segment or Geography

By Segment
By Geography
Quiver Logo

No Revenue by Segment data for this ticker

Revenue Breakdown Dashboard
Quiver Logo

No Revenue by Geography data for this ticker

Revenue Breakdown Dashboard
CRBU Income Statement
CRBU Balance Sheet
CRBU Cash Flow
U.S. Patents

New CRBU patent grants

  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Jul. 21, 2026
  • Patent Title: Dual guide crispr hybrid dna/rna polynucleotides and methods of use Jun. 02, 2026
  • Patent Title: Anti-ror1 antibody and ror1-targeting engineered cells Dec. 09, 2025
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Oct. 07, 2025
  • Patent Title: Method of capturing crispr endonuclease cleavage products Sep. 16, 2025
  • Patent Title: Engineered cascade components and cascade complexes Feb. 18, 2025
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Mar. 26, 2024
  • Patent Title: Engineered cascade components and cascade complexes Jan. 17, 2023
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Nov. 22, 2022
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Oct. 18, 2022
  • Patent Title: Methods of use of crispr cpf1 hybrid dna/rna polynucleotides Oct. 04, 2022
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Apr. 26, 2022
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Apr. 12, 2022
  • Patent Title: Crispr hybrid dna/rna polynucleotides and methods of use Feb. 01, 2022
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jan. 18, 2022
  • Patent Title: Methods for using dna repair for cell engineering Oct. 26, 2021
  • Patent Title: Bcma-car-natural killer (nk) cells and methods related thereto Oct. 12, 2021
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Sep. 07, 2021
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Jun. 01, 2021
  • Patent Title: Engineered nucleic acid-targeting nucleic acids May. 11, 2021
  • Patent Title: Method of target cleaving using crispr hybrid dna/rna polynucleotides Apr. 27, 2021
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Mar. 23, 2021
  • Patent Title: Humanized bcma antibody and bcma-car-t cells Feb. 23, 2021
  • Patent Title: Engineered cascade components and cascade complexes Sep. 22, 2020
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jul. 14, 2020
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Jul. 14, 2020
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Dec. 10, 2019
  • Patent Title: Engineered cascade components and cascade complexes Oct. 29, 2019
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Oct. 08, 2019
  • Patent Title: Engineered cascade components and cascade complexes Jun. 25, 2019
  • Patent Title: Methods for increasing cas9-mediated engineering efficiency May. 15, 2018
  • Patent Title: Engineered nucleic acid-targeting nucleic acids May. 15, 2018
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides May. 15, 2018
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides May. 15, 2018
  • Patent Title: Cells comprising engineered nucleic-acid targeting nucleic acids May. 01, 2018
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Mar. 06, 2018
  • Patent Title: Methods of modifying a target nucleic acid with an argonaute Feb. 27, 2018
  • Patent Title: Modified cascade ribonucleoproteins and uses thereof Feb. 06, 2018
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Nov. 14, 2017
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Nov. 14, 2017
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Nov. 07, 2017
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Oct. 31, 2017
  • Patent Title: Engineered nucleic acid-targeting nucleic acids Sep. 26, 2017
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Aug. 29, 2017
  • Patent Title: Methods of using engineered nucleic-acid targeting nucleic acids Aug. 29, 2017
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Aug. 08, 2017
  • Patent Title: Engineered nucleic-acid targeting nucleic acids Jun. 13, 2017
  • Patent Title: Compositions and methods of engineered crispr-cas9 systems using split-nexus cas9-associated polynucleotides Feb. 28, 2017
  • Patent Title: Compostions and methods of nucleic acid-targeting nucleic acids Aug. 09, 2016
  • Patent Title: Compositions and methods of nucleic acid-targeting nucleic acids Feb. 16, 2016
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
Government Contracts

Estimated quarterly amount awarded to CRBU from public contracts

Quiver Logo

No recent Government Contracts for this ticker

Government Contracts Dashboard
CRBU News

Recent insights relating to CRBU

CNBC Recommendations

Recent picks made for CRBU stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in CRBU

CRBU Analyst Ratings

CRBU Stock Forecasts
...

  • ... Highest Price Target
  • ... Median Price Target
  • ... Lowest Price Target
CRBU Analyst Forecasts
Analyst
Firm
Current
Previous
Date
Frequently Asked Questions
  • Is $CRBU stock a Buy, Sell, or Hold?

  • What is the price target for $CRBU stock?

* Analyst consensus is not financial advice. Please see our data disclaimers .

CRBU Top Shareholders
Shareholder
Shares Held
CRBU Options Owners
Shareholder
Security
Underlying Shares
Frequently Asked Questions
  • Who owns $CRBU stock?

  • Who owns the most shares of $CRBU stock?

  • What funds own $CRBU stock?

* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.

CRBU Stock Smart Score

The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.

The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.
?

Sign Up to view CRBU Smart Score

Score Breakdown
Bull Case vs Bear Case

See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.

Example:

Bulls Say:

The Bulls Say summary highlights positive aspects of the stock.

Bears Say:

The Bears Say summary points out potential risks and negative aspects of the stock.

Show More
About CRBU

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.

  • Address Berkeley, CA
  • Market Cap 138.3 million
  • Employees 97
  • Industrial Classification Biological Products, (No Diagnostic Substances)

Caribou Biosciences, Inc. Common Stock (CRBU) Historical Stock Prices

Caribou Biosciences, Inc. Common Stock (CRBU) closed at $1.29 on September 23, 2026. Over the past year its adjusted close ranged from $1.25 to $2.84. Daily prices go back to July 23, 2021, 1,298 trading days in all.

  • 1 month-21.34%
  • 3 months-22.29%
  • Year to date-18.87%
  • 1 year-30.65%
  • 3 years-74.66%
  • 5 years-94.68%
  • Max-92.10%
See every congressional and insider trade on the CRBU price chart

Quiver Premium charts CRBU's full daily history since 2014 with each congressional purchase and sale and every open-market insider purchase marked on the price line, with hover details for each trade.

Upgrade to Premium

Last 12 months, newest first

Access Raw Data Daily prices since 2014 for every ticker, through the Quiver API
DateOpenHighLowCloseAdj. CloseVolume
Sep 23, 2026 1.34 1.36 1.29 1.29 1.29 700,029
Sep 22, 2026 1.32 1.36 1.31 1.34 1.34 1,217,330
Sep 21, 2026 1.31 1.35 1.29 1.30 1.30 753,310
Sep 18, 2026 1.33 1.34 1.30 1.30 1.30 1,853,974
Sep 17, 2026 1.27 1.33 1.26 1.31 1.31 1,257,062
Sep 16, 2026 1.28 1.29 1.25 1.25 1.25 969,353
Sep 15, 2026 1.31 1.31 1.25 1.27 1.27 1,692,439
Sep 14, 2026 1.27 1.33 1.25 1.29 1.29 1,685,847
Sep 11, 2026 1.38 1.40 1.26 1.27 1.27 2,433,878
Sep 10, 2026 1.43 1.44 1.35 1.37 1.37 1,261,006
Sep 9, 2026 1.54 1.54 1.44 1.44 1.44 1,768,265
Sep 8, 2026 1.57 1.58 1.54 1.54 1.54 717,627
Sep 4, 2026 1.57 1.60 1.55 1.57 1.57 1,329,447
Sep 3, 2026 1.61 1.61 1.53 1.57 1.57 1,349,959
Sep 2, 2026 1.55 1.62 1.55 1.60 1.60 770,671
Sep 1, 2026 1.53 1.59 1.52 1.55 1.55 756,279
Aug 31, 2026 1.61 1.63 1.52 1.54 1.54 1,010,331
Aug 28, 2026 1.66 1.67 1.60 1.62 1.62 666,589
Aug 27, 2026 1.67 1.69 1.64 1.66 1.66 901,154
Aug 26, 2026 1.75 1.75 1.64 1.65 1.65 841,305
Aug 25, 2026 1.65 1.76 1.65 1.76 1.76 1,380,392
Aug 24, 2026 1.68 1.69 1.61 1.64 1.64 762,660
Aug 21, 2026 1.64 1.69 1.61 1.66 1.66 1,162,457
Aug 20, 2026 1.64 1.65 1.58 1.61 1.61 892,576
Aug 19, 2026 1.60 1.66 1.58 1.64 1.64 1,569,682
Aug 18, 2026 1.56 1.58 1.52 1.56 1.56 557,675
Aug 17, 2026 1.57 1.59 1.55 1.57 1.57 952,143
Aug 14, 2026 1.61 1.61 1.52 1.58 1.58 1,188,579
Aug 13, 2026 1.72 1.72 1.60 1.61 1.61 1,143,264
Aug 12, 2026 1.69 1.71 1.66 1.70 1.70 717,444
Aug 11, 2026 1.68 1.71 1.65 1.69 1.69 995,207
Aug 10, 2026 1.65 1.68 1.63 1.66 1.66 760,169
Aug 7, 2026 1.65 1.67 1.62 1.65 1.65 806,039
Aug 6, 2026 1.61 1.68 1.59 1.64 1.64 1,059,396
Aug 5, 2026 1.59 1.66 1.58 1.61 1.61 1,115,904
Aug 4, 2026 1.50 1.58 1.50 1.57 1.57 1,335,856
Aug 3, 2026 1.47 1.50 1.43 1.50 1.50 1,391,398
Jul 31, 2026 1.53 1.53 1.43 1.46 1.46 1,127,984
Jul 30, 2026 1.48 1.52 1.45 1.51 1.51 916,460
Jul 29, 2026 1.50 1.51 1.44 1.47 1.47 1,300,486
Jul 28, 2026 1.60 1.60 1.47 1.49 1.49 1,961,540
Jul 27, 2026 1.60 1.65 1.58 1.59 1.59 731,615
Jul 24, 2026 1.62 1.64 1.57 1.57 1.57 946,833
Jul 23, 2026 1.62 1.65 1.60 1.63 1.63 824,433
Jul 22, 2026 1.65 1.67 1.63 1.66 1.66 1,019,859
Jul 21, 2026 1.61 1.73 1.59 1.65 1.65 1,607,357
Jul 20, 2026 1.64 1.67 1.59 1.62 1.62 1,150,446
Jul 17, 2026 1.62 1.69 1.60 1.65 1.65 1,447,861
Jul 16, 2026 1.70 1.72 1.64 1.66 1.66 1,843,194
Jul 15, 2026 1.76 1.77 1.71 1.73 1.73 1,215,025
Jul 14, 2026 1.81 1.83 1.75 1.75 1.75 3,961,253
Jul 13, 2026 1.91 1.91 1.76 1.80 1.80 1,954,841
Jul 10, 2026 1.92 1.93 1.75 1.93 1.93 3,477,068
Jul 9, 2026 1.93 1.99 1.84 1.94 1.94 2,207,400
Jul 8, 2026 1.88 2.11 1.85 1.94 1.94 3,910,907
Jul 7, 2026 1.84 1.93 1.75 1.92 1.92 2,347,654
Jul 6, 2026 1.83 1.85 1.80 1.83 1.83 1,092,049
Jul 2, 2026 1.77 1.92 1.77 1.82 1.82 1,868,938
Jul 1, 2026 1.76 1.78 1.73 1.76 1.76 1,696,835
Jun 30, 2026 1.81 1.81 1.73 1.76 1.76 1,417,035
Jun 29, 2026 1.70 1.82 1.67 1.77 1.77 2,810,336
Jun 26, 2026 1.57 1.73 1.56 1.68 1.68 13,887,977
Jun 25, 2026 1.68 1.69 1.56 1.57 1.57 1,641,722
Jun 24, 2026 1.67 1.71 1.62 1.66 1.66 1,801,142
Jun 23, 2026 1.62 1.72 1.62 1.66 1.66 2,098,538
Jun 22, 2026 1.63 1.70 1.62 1.64 1.64 1,771,515
Jun 18, 2026 1.66 1.70 1.57 1.64 1.64 2,539,772
Jun 17, 2026 1.66 1.78 1.63 1.64 1.64 1,737,019
Jun 16, 2026 1.66 1.73 1.63 1.69 1.69 2,087,763
Jun 15, 2026 1.61 1.69 1.61 1.66 1.66 1,707,645
Jun 12, 2026 1.74 1.77 1.59 1.59 1.59 2,301,205
Jun 11, 2026 1.80 1.82 1.61 1.66 1.66 2,704,756
Jun 10, 2026 1.83 1.88 1.77 1.79 1.79 967,767
Jun 9, 2026 1.85 1.92 1.78 1.84 1.84 1,632,275
Jun 8, 2026 1.97 1.97 1.83 1.84 1.84 1,656,008
Jun 5, 2026 2.06 2.06 1.91 1.92 1.92 1,677,247
Jun 4, 2026 2.01 2.15 2.01 2.06 2.06 1,745,539
Jun 3, 2026 2.29 2.30 2.00 2.00 2.00 2,141,719
Jun 2, 2026 2.45 2.45 2.29 2.32 2.32 1,738,579
Jun 1, 2026 2.36 2.49 2.31 2.43 2.43 1,966,686
May 29, 2026 2.33 2.40 2.27 2.36 2.36 1,394,446
May 28, 2026 2.30 2.37 2.25 2.31 2.31 1,539,814
May 27, 2026 2.18 2.40 2.14 2.31 2.31 3,737,500
May 26, 2026 2.10 2.25 2.08 2.16 2.16 1,947,062
May 22, 2026 2.00 2.12 1.97 2.10 2.10 1,396,555
May 21, 2026 1.95 2.02 1.88 1.99 1.99 1,368,310
May 20, 2026 1.98 2.04 1.97 2.00 2.00 1,709,882
May 19, 2026 2.05 2.10 1.95 1.97 1.97 1,801,746
May 18, 2026 2.16 2.28 1.98 2.07 2.07 2,047,858
May 15, 2026 2.13 2.19 2.09 2.14 2.14 1,923,805
May 14, 2026 2.13 2.32 1.99 2.14 2.14 3,446,874
May 13, 2026 2.03 2.15 2.00 2.12 2.12 1,670,966
May 12, 2026 2.04 2.08 1.97 2.03 2.03 1,762,455
May 11, 2026 1.97 2.19 1.95 2.03 2.03 1,891,311
May 8, 2026 1.90 1.99 1.89 1.94 1.94 892,097
May 7, 2026 1.95 1.96 1.84 1.88 1.88 1,668,434
May 6, 2026 1.95 1.97 1.93 1.95 1.95 985,878
May 5, 2026 1.95 1.99 1.89 1.93 1.93 992,511
May 4, 2026 1.85 1.97 1.85 1.91 1.91 1,258,164
May 1, 2026 1.91 1.91 1.83 1.87 1.87 1,136,737
Apr 30, 2026 1.93 1.96 1.84 1.88 1.88 1,024,315
Apr 29, 2026 2.08 2.08 1.91 1.92 1.92 1,218,407
Apr 28, 2026 2.12 2.16 2.06 2.08 2.08 1,135,306
Apr 27, 2026 2.18 2.26 2.10 2.13 2.13 2,150,497
Apr 24, 2026 2.26 2.27 2.11 2.13 2.13 1,915,957
Apr 23, 2026 2.33 2.39 2.23 2.26 2.26 1,472,396
Apr 22, 2026 2.29 2.39 2.26 2.36 2.36 1,443,101
Apr 21, 2026 2.30 2.33 2.23 2.25 2.25 1,941,357
Apr 20, 2026 2.21 2.32 2.17 2.29 2.29 1,965,577
Apr 17, 2026 2.22 2.26 2.14 2.20 2.20 1,808,590
Apr 16, 2026 2.21 2.21 2.10 2.15 2.15 2,089,139
Apr 15, 2026 2.14 2.22 2.13 2.20 2.20 1,957,287
Apr 14, 2026 1.97 2.17 1.97 2.12 2.12 2,679,486
Apr 13, 2026 1.91 1.99 1.90 1.95 1.95 1,019,667
Apr 10, 2026 1.96 1.98 1.90 1.93 1.93 821,295
Apr 9, 2026 1.95 2.00 1.93 1.96 1.96 891,128
Apr 8, 2026 1.95 2.00 1.91 1.95 1.95 1,072,886
Apr 7, 2026 1.94 1.94 1.84 1.86 1.86 1,006,541
Apr 6, 2026 1.95 2.00 1.92 1.95 1.95 633,074
Apr 2, 2026 1.91 2.00 1.89 1.94 1.94 1,063,880
Apr 1, 2026 1.92 2.04 1.92 1.99 1.99 1,256,631
Mar 31, 2026 1.80 2.00 1.80 1.90 1.90 1,605,510
Mar 30, 2026 1.79 1.81 1.69 1.72 1.72 1,272,462
Mar 27, 2026 1.88 1.91 1.76 1.78 1.78 896,001
Mar 26, 2026 1.84 2.00 1.84 1.91 1.91 1,085,471
Mar 25, 2026 1.85 1.96 1.85 1.88 1.88 641,911
Mar 24, 2026 1.84 1.88 1.76 1.82 1.82 940,635
Mar 23, 2026 1.89 1.92 1.82 1.86 1.86 789,846
Mar 20, 2026 1.96 1.97 1.85 1.87 1.87 958,720
Mar 19, 2026 1.87 1.98 1.83 1.97 1.97 1,554,225
Mar 18, 2026 1.96 2.00 1.89 1.91 1.91 1,027,606
Mar 17, 2026 1.88 1.97 1.86 1.97 1.97 930,635
Mar 16, 2026 1.89 2.00 1.86 1.87 1.87 1,351,166
Mar 13, 2026 1.92 1.93 1.84 1.88 1.88 760,651
Mar 12, 2026 1.93 1.95 1.86 1.89 1.89 700,673
Mar 11, 2026 2.00 2.02 1.93 1.97 1.97 995,869
Mar 10, 2026 2.00 2.06 1.96 2.03 2.03 2,310,052
Mar 9, 2026 1.79 2.00 1.79 1.97 1.97 1,634,567
Mar 6, 2026 1.66 1.83 1.66 1.82 1.82 1,294,543
Mar 5, 2026 1.79 1.81 1.67 1.71 1.71 1,101,398
Mar 4, 2026 1.78 1.86 1.74 1.80 1.80 745,102
Mar 3, 2026 1.80 1.80 1.73 1.76 1.76 839,087
Mar 2, 2026 1.78 1.89 1.76 1.84 1.84 1,148,342
Feb 27, 2026 1.95 2.01 1.89 1.90 1.90 1,371,606
Feb 26, 2026 1.93 2.02 1.87 1.99 1.99 1,217,196
Feb 25, 2026 2.15 2.18 1.92 1.95 1.95 2,541,810
Feb 24, 2026 1.90 2.22 1.87 2.14 2.14 4,617,511
Feb 23, 2026 1.80 1.93 1.78 1.92 1.92 1,864,543
Feb 20, 2026 1.75 1.85 1.71 1.80 1.80 1,762,773
Feb 19, 2026 1.61 1.77 1.58 1.76 1.76 1,402,789
Feb 18, 2026 1.55 1.62 1.53 1.62 1.62 681,476
Feb 17, 2026 1.57 1.58 1.51 1.55 1.55 629,055
Feb 13, 2026 1.52 1.64 1.52 1.58 1.58 1,515,789
Feb 12, 2026 1.59 1.59 1.47 1.52 1.52 800,485
Feb 11, 2026 1.58 1.60 1.48 1.59 1.59 1,121,088
Feb 10, 2026 1.63 1.63 1.57 1.57 1.57 1,357,746
Feb 9, 2026 1.58 1.65 1.53 1.63 1.63 760,849
Feb 6, 2026 1.52 1.58 1.50 1.57 1.57 1,015,727
Feb 5, 2026 1.60 1.65 1.45 1.48 1.48 1,268,066
Feb 4, 2026 1.59 1.64 1.49 1.62 1.62 2,184,501
Feb 3, 2026 1.55 1.74 1.48 1.56 1.56 2,391,289
Feb 2, 2026 1.40 1.48 1.38 1.46 1.46 1,157,479
Jan 30, 2026 1.46 1.47 1.39 1.41 1.41 790,200
Jan 29, 2026 1.53 1.53 1.47 1.48 1.48 665,952
Jan 28, 2026 1.56 1.56 1.49 1.52 1.52 633,600
Jan 27, 2026 1.53 1.58 1.51 1.55 1.55 488,139
Jan 26, 2026 1.52 1.53 1.47 1.53 1.53 784,122
Jan 23, 2026 1.61 1.63 1.53 1.53 1.53 957,275
Jan 22, 2026 1.50 1.65 1.48 1.62 1.62 1,079,420
Jan 21, 2026 1.40 1.50 1.40 1.49 1.49 1,394,864
Jan 20, 2026 1.44 1.45 1.39 1.39 1.39 1,543,524
Jan 16, 2026 1.55 1.56 1.45 1.46 1.46 2,637,107
Jan 15, 2026 1.62 1.63 1.55 1.56 1.56 1,049,545
Jan 14, 2026 1.60 1.62 1.58 1.61 1.61 724,268
Jan 13, 2026 1.60 1.64 1.56 1.59 1.59 1,035,757
Jan 12, 2026 1.64 1.65 1.52 1.58 1.58 2,562,351
Jan 9, 2026 1.72 1.73 1.64 1.66 1.66 711,558
Jan 8, 2026 1.76 1.76 1.68 1.69 1.69 493,349
Jan 7, 2026 1.72 1.80 1.70 1.77 1.77 1,006,520
Jan 6, 2026 1.62 1.72 1.61 1.72 1.72 858,109
Jan 5, 2026 1.59 1.61 1.54 1.61 1.61 726,822
Jan 2, 2026 1.59 1.60 1.54 1.59 1.59 881,870
Dec 31, 2025 1.57 1.60 1.55 1.59 1.59 1,249,660
Dec 30, 2025 1.64 1.65 1.58 1.59 1.59 1,117,508
Dec 29, 2025 1.69 1.71 1.64 1.65 1.65 1,107,832
Dec 26, 2025 1.70 1.72 1.65 1.70 1.70 780,169
Dec 24, 2025 1.65 1.73 1.64 1.72 1.72 332,998
Dec 23, 2025 1.72 1.72 1.63 1.66 1.66 891,813
Dec 22, 2025 1.70 1.74 1.67 1.72 1.72 689,825
Dec 19, 2025 1.64 1.70 1.62 1.68 1.68 1,865,716
Dec 18, 2025 1.63 1.75 1.62 1.63 1.63 1,098,123
Dec 17, 2025 1.69 1.73 1.62 1.62 1.62 956,193
Dec 16, 2025 1.72 1.74 1.65 1.69 1.69 1,029,651
Dec 15, 2025 1.84 1.85 1.71 1.71 1.71 1,182,143
Dec 12, 2025 1.86 1.88 1.79 1.79 1.79 1,136,142
Dec 11, 2025 1.88 1.90 1.82 1.86 1.86 1,055,625
Dec 10, 2025 1.87 1.91 1.81 1.90 1.90 929,729
Dec 9, 2025 1.90 1.90 1.83 1.87 1.87 719,547
Dec 8, 2025 1.92 1.96 1.86 1.89 1.89 1,022,230
Dec 5, 2025 1.93 1.95 1.85 1.90 1.90 726,780
Dec 4, 2025 1.87 1.97 1.84 1.94 1.94 954,209
Dec 3, 2025 1.76 1.87 1.76 1.86 1.86 808,232
Dec 2, 2025 1.78 1.82 1.75 1.76 1.76 942,376
Dec 1, 2025 1.89 1.89 1.76 1.77 1.77 1,161,480
Nov 28, 2025 1.90 1.97 1.87 1.94 1.94 407,372
Nov 26, 2025 1.86 1.90 1.80 1.88 1.88 797,583
Nov 25, 2025 1.87 1.89 1.76 1.87 1.87 1,074,645
Nov 24, 2025 1.76 1.87 1.75 1.87 1.87 1,004,442
Nov 21, 2025 1.74 1.86 1.73 1.75 1.75 1,186,531
Nov 20, 2025 1.84 1.92 1.72 1.75 1.75 1,533,213
Nov 19, 2025 1.85 1.89 1.80 1.82 1.82 924,084
Nov 18, 2025 1.87 1.92 1.83 1.87 1.87 1,196,656
Nov 17, 2025 1.98 2.01 1.85 1.89 1.89 1,353,149
Nov 14, 2025 1.94 2.07 1.92 1.99 1.99 1,379,425
Nov 13, 2025 2.30 2.30 1.96 1.99 1.99 1,922,058
Nov 12, 2025 2.24 2.27 2.11 2.26 2.26 1,492,682
Nov 11, 2025 2.05 2.25 2.04 2.24 2.24 1,493,318
Nov 10, 2025 2.14 2.26 2.01 2.07 2.07 1,993,741
Nov 7, 2025 2.02 2.12 1.93 2.09 2.09 2,962,004
Nov 6, 2025 2.25 2.26 2.08 2.14 2.14 1,851,647
Nov 5, 2025 2.28 2.29 2.09 2.19 2.19 2,121,621
Nov 4, 2025 2.40 2.47 2.13 2.17 2.17 5,149,911
Nov 3, 2025 3.40 3.54 2.38 2.43 2.43 68,354,934
Oct 31, 2025 2.31 2.47 2.27 2.42 2.42 564,415
Oct 30, 2025 2.35 2.44 2.32 2.32 2.32 474,772
Oct 29, 2025 2.48 2.49 2.35 2.37 2.37 532,748
Oct 28, 2025 2.46 2.59 2.40 2.47 2.47 615,686
Oct 27, 2025 2.51 2.52 2.35 2.45 2.45 838,525
Oct 24, 2025 2.57 2.60 2.45 2.49 2.49 656,754
Oct 23, 2025 2.52 2.59 2.47 2.50 2.50 377,059
Oct 22, 2025 2.83 2.85 2.44 2.53 2.53 1,421,485
Oct 21, 2025 2.83 2.97 2.75 2.84 2.84 1,132,052
Oct 20, 2025 2.70 2.92 2.68 2.82 2.82 1,174,375
Oct 17, 2025 2.63 2.70 2.58 2.63 2.63 668,897
Oct 16, 2025 2.83 2.94 2.64 2.67 2.67 951,226
Oct 15, 2025 2.46 2.84 2.43 2.84 2.84 1,963,099
Oct 14, 2025 2.33 2.51 2.27 2.44 2.44 1,030,934
Oct 13, 2025 2.55 2.60 2.37 2.38 2.38 767,312
Oct 10, 2025 2.76 2.77 2.43 2.49 2.49 1,711,723
Oct 9, 2025 2.76 2.87 2.70 2.75 2.75 1,482,161
Oct 8, 2025 2.44 2.75 2.40 2.68 2.68 2,722,814
Oct 7, 2025 2.36 2.44 2.24 2.43 2.43 1,434,078
Oct 6, 2025 2.30 2.37 2.25 2.34 2.34 817,513
Oct 3, 2025 2.26 2.34 2.18 2.27 2.27 1,344,327
Oct 2, 2025 2.28 2.36 2.17 2.23 2.23 1,386,388
Oct 1, 2025 2.32 2.39 2.23 2.26 2.26 1,631,681
Sep 30, 2025 2.31 2.37 2.19 2.33 2.33 1,162,477
Sep 29, 2025 2.18 2.31 2.10 2.30 2.30 1,582,270
Sep 26, 2025 1.93 2.16 1.84 2.13 2.13 1,585,066
Sep 25, 2025 2.10 2.11 1.90 1.93 1.93 1,263,039
Sep 24, 2025 1.86 2.18 1.86 2.13 2.13 2,177,105
Sep 23, 2025 1.97 1.97 1.85 1.86 1.86 902,512

Open, high, low and close are the prices as traded. Adjusted close accounts for splits and dividends, and is what the chart and returns use. Where a company changed its ticker, its history under the old symbol is included.

Need daily prices for every ticker, in code?

The Quiver API serves daily prices back to 2014 alongside congressional trades, insider trades, 13F holdings and lobbying, all under one key and inside Claude or ChatGPT through our MCP server.

Explore the Quiver API
Caribou Biosciences, Inc. Common Stock Executive Compensation

We estimate that -- received a compensation of -- in --, making them the highest paid executive at CRBU, per a recent SEC DEF 14A filing.



Name
Role
Salary
Bonus
Stock/Option Awards
Total Compensation